News
Zacharoula Sidiropoulou: Bringing Together Leading Minds to Drive Real Progress in Breast Cancer Care - OncoDaily
6+ hour, 45+ min ago (137+ words) What an incredible start to our 1st Edition of Post-Graduation Cource in Breast Diseases The first two days have exceeded all expectations. Our expert speakers (In's Moruj'o, Rita Sampaio, Margarida Brito and Fernando Os'rio) have delivered profound insights, challenging perspectives and…...
Matteo Lambertini: First Time at The Asia-Pacific Breast Cancer Summit APBCS - OncoDaily
6+ day, 13+ hour ago (117+ words) OncoDaily is a specialized news and information platform that provides daily updates on oncology research, treatments, clinical trials, and advancements in cancer care. It serves healthcare professionals, researchers, and patients by delivering timely and accurate insights into the latest developments…...
Naoto T. Ueno: How Payload Choice Can Extend Clinical Benefit in Breast Cancer - OncoDaily
1+ week, 7+ hour ago (101+ words) Naoto T Ueno, Director of the University of Hawaii Cancer Center, shared a post on'X: "Tumors resistant to one ADC can regain sensitivity to another ADC with a different payload. Our work shows payload choice-not just target expression-may extend clinical…...
Najihah Binti Abu Bakar Joins Local Faculty for Key Breast Cancer Sessions - APBCS 2026 - OncoDaily
1+ week, 2+ day ago (109+ words) 14th Asia-Pacific Breast Cancer Summit 2026shared a post onLinkedIn: "We are honored to welcome Dr. Najihah Binti Abu Bakar as part of our Local Faculty at the Asia-Pacific Breast Cancer Summit 2026. Dr. Najihah is a Clinical Oncologist at Hospital Kuala Lumpur (HKL)....
Susheel Kumar Yeshala: Rethinking Risk and Precision in HR+/HER2-Negative Breast Cancer - OncoDaily
1+ week, 2+ day ago (184+ words) Susheel Kumar Yeshala, Consultant Medical Oncologist at American Oncology Institute, shared a post on'LinkedIn: "A wonderful evening of learning and reflection on HR+/HER2-negative breast cancer. -HR+/HER2-negative breast cancer is a molecular umbrella, not a single disease. -Includes luminal…...
Escalation or De-Escalation? Strategies in HER2+ Breast Cancer Treatment - Oncology News, Insights, Stories by OncoDaily
2+ week, 2+ day ago (123+ words) JUPITER-06 Final Overall Survival and Genomic Biomarker Analysis in Advanced ESCC PICI Collaborates with ASCO to Support Future Leaders in Cancer Immunotherapy In Memory of Kirsty Duncan: A Life Devoted to Science, Health, and Equity Pat Soon-Shiong: The Beginning of…...
15th European Breast Cancer Conference (EBCC-15) - Oncology News, Insights, Stories by OncoDaily
2+ week, 2+ day ago (72+ words) JUPITER-06 Final Overall Survival and Genomic Biomarker Analysis in Advanced ESCC PICI Collaborates with ASCO to Support Future Leaders in Cancer Immunotherapy In Memory of Kirsty Duncan: A Life Devoted to Science, Health, and Equity Fabio Ynoe de Moraes has…...
Eugenie Spiguel Joins APBCS 2026 to Advance Patient-Centred Breast Cancer Care - OncoDaily
2+ week, 2+ day ago (193+ words) OncoDaily is a specialized news and information platform that provides daily updates on oncology research, treatments, clinical trials, and advancements in cancer care. It serves healthcare professionals, researchers, and patients by delivering timely and accurate insights into the latest developments…...
Aumilto Silva: PATINA Trial - A New Maintenance Standard for HR+/HER2+ Breast Cancer - OncoDaily
2+ week, 2+ day ago (91+ words) Aumilto Silva, Medical Oncologist and Clinical Research at Hospital Santa Catarina Paulista, shared a post on X: Design: Phase 3, randomized Maintenance anti-HER2 + endocrine therapy with vs without palbociclib ~15-month absolute PFS gain with CDK4/6 inhibition Rather than escalating to more intensive therapies,…...
Paolo Tarantino: PATINA Trial Brings Metastatic Breast Cancer Closer to a Chronic Disease - OncoDaily
2+ week, 2+ day ago (153+ words) Paolo Tarantino,2025 Yvonne's "Top Voice" Award Winner, Clinical Research Fellow at Dana-Farber Cancer Institute, Visiting Professor at McGill University, shared a post onLinkedIn: "We all remained jaw-open when we first saw the results from PATINA presented. They are now published…...